Electrospun PLA/PCL Composite Scaffolds as Platforms for Investigating Colorectal Cancer Cell Plasticity.
1/5 보강
Electrospun nanofibrous scaffolds are promising tools for cancer modeling due to their tunable architecture and biocompatibility.
APA
Chakraborty S, Mathew BT, et al. (2026). Electrospun PLA/PCL Composite Scaffolds as Platforms for Investigating Colorectal Cancer Cell Plasticity.. ACS omega, 11(12), 18987-18998. https://doi.org/10.1021/acsomega.5c11453
MLA
Chakraborty S, et al.. "Electrospun PLA/PCL Composite Scaffolds as Platforms for Investigating Colorectal Cancer Cell Plasticity.." ACS omega, vol. 11, no. 12, 2026, pp. 18987-18998.
PMID
41939393
Abstract
Electrospun nanofibrous scaffolds are promising tools for cancer modeling due to their tunable architecture and biocompatibility. This study compares the effects of PLA, PCL, and their 1:1 blend (PLA/PCL) scaffolds on colorectal cancer (CRC) cell lines HT-29 and HCT116. Morphological and physicochemical analyses of the scaffolds confirmed uniform, bead-free fibers with slight alterations in crystallinity and hydrophobicity. Scaffold-specific biological responses included differences in cell morphology, viability, proliferation, metabolism, and gene expression related to EMT, stemness, ECM interaction, and adhesion. PLA/PCL scaffolds indicated enhanced cell adhesion and proliferation and retained metabolic activity over time. Gene expression profiling revealed significant upregulation of EMT (, ) and ECM () markers in both cell lines cultured on the PLA/PCL composite, with HT-29 showing elevated stemness () and adhesion (), while HCT116 exhibited a hybrid EMT phenotype. Collectively, this work highlights the potential of PLA/PCL electrospun scaffolds to bridge conventional 2D cultures and complex 3D systems, thereby advancing colorectal cancer modeling and therapeutic testing for preclinical evaluations.
같은 제1저자의 인용 많은 논문 (4)
- Measuring and predicting where and when pathologists focus their visual attention while grading whole slide images of cancer.
- Targeting NHEJ activates STING signaling through MYC degradation to boost antitumor immunity in SCLC.
- A STAT3 degrader demonstrates efficacy in venetoclax resistant acute myeloid leukemia.
- Cortisol-resistant CAR-NK cells overcome steroid-induced immunosuppression in lung cancer.